These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 2509412)

  • 1. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.
    Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():143-7. PubMed ID: 2509412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP; Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
    Tasaka K; Ishida A; Chinzei T
    Jpn J Antibiot; 2002 Apr; 55(2):181-6. PubMed ID: 12071095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
    Livermore DM; Yang YJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems.
    Pournaras S; Ikonomidis A; Markogiannakis A; Spanakis N; Maniatis AN; Tsakris A
    J Med Microbiol; 2007 Jan; 56(Pt 1):66-70. PubMed ID: 17172519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia.
    García-Rodríguez JA; García Sánchez JE; Muñoz Bellido JL; García Sánchez E; García García MI
    J Chemother; 1991 Jun; 3(3):143-6. PubMed ID: 1919651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of meropenem against clinical isolates obtained in Canada.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():47-55. PubMed ID: 2808216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    Antimicrob Agents Chemother; 1995 Mar; 39(3):731-4. PubMed ID: 7793881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of carbapenem-resistant Pseudomonas aeruginosa strains in patients with ventilator-associated pneumonia in intensive care units.
    Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Bakšytė G; Macas A; Sakalauskas R
    Medicina (Kaunas); 2011; 47(12):652-6. PubMed ID: 22370463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    Diagn Microbiol Infect Dis; 1997 Oct; 29(2):81-6. PubMed ID: 9368083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kaynar-Tascioglu J; Kaya B; Goktas P
    Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
    Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa.
    Margaret BS; Drusano GL; Standiford HC
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():161-7. PubMed ID: 2509413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial in vitro-activity of meropenem against 200 clinical isolates in comparison to 11 selected antibiotics.
    Lang C; Beuth J; Ko HL; Tunggal L; Pulverer G
    Zentralbl Bakteriol; 1992 Dec; 277(4):485-92. PubMed ID: 1303691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
    Schito GC; Sanna A; Chezzi C; Ravizzola G; Leone F; Molinari G; Menozzi MG; Pirali F
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.